2023
Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 37311914, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsExtracardiac uptakePYP uptakeCardiac amyloidosisBone uptakeActionable findingsTiming of scansTransthyretin cardiac amyloidosisHeart failureBreast uptakeMean ageBlack raceRenal uptakeHispanic ethnicityThyroid uptakeATTR-CANuclear scintigraphyHispanic participantsTechnetium pyrophosphateNuclear imagingPYP scanPopulation studiesSelf-identified BlackAdditional testingAmyloidosisSubjects
2020
Advances in PET-Based Cardiac Amyloid Radiotracers
Gallegos C, Miller EJ. Advances in PET-Based Cardiac Amyloid Radiotracers. Current Cardiology Reports 2020, 22: 40. PMID: 32430600, DOI: 10.1007/s11886-020-01284-3.Peer-Reviewed Original ResearchConceptsPositron emission tomographyCardiac amyloidosisAmyloid depositionAmyloid radiotracersCardiac amyloid depositionCare of patientsTransthyretin cardiac amyloidosisCardiac imaging techniquesCongo red stainingPurpose of ReviewWeNovel positron emission tomographyEndomyocardial biopsyImaging featuresAmyloid depositsUnmet needInvasive methodEmission tomographyAmyloidosisGold standardAdditive valueRed stainingBiopsyFurther dataDiagnosisRecent studies
2019
SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS
Higgins A, Annapureddy A, Wang Y, Minges K, Lampert R, Rosenfeld L, Jacoby D, Curtis J, Miller E, Freeman J. SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 694. DOI: 10.1016/s0735-1097(19)31302-6.Peer-Reviewed Original Research
2018
Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis
Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. Journal Of Cardiac Failure 2018, 24: 131-133. PMID: 29305186, DOI: 10.1016/j.cardfail.2017.12.005.Peer-Reviewed Original Research
2016
National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy
Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, Miller EJ. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. Journal Of Nuclear Cardiology 2016, 24: 1094-1097. PMID: 27016106, DOI: 10.1007/s12350-016-0478-3.Peer-Reviewed Original ResearchConceptsCardiac amyloidosisCA diagnosisContralateral lung ratioTransthyretin cardiac amyloidosisLung ratioDiagnostic modalitiesMost centersTest utilizationWeb-based surveyScintigraphyMultiple centersDiagnosisQuantification of uptakeLow penetranceNational surveyAmyloidosisNational patternsCardiologistsDose